Your browser doesn't support javascript.
loading
Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma.
López-Carrasco, Amparo; Berbegall, Ana P; Martín-Vañó, Susana; Blanquer-Maceiras, Maite; Castel, Victoria; Navarro, Samuel; Noguera, Rosa.
Afiliação
  • López-Carrasco A; Department of Pathology, Medical School, University of Valencia-INCLIVA, 46010 Valencia, Spain.
  • Berbegall AP; CIBER of Cancer (CIBERONC), 28029 Madrid, Spain.
  • Martín-Vañó S; Department of Pathology, Medical School, University of Valencia-INCLIVA, 46010 Valencia, Spain.
  • Blanquer-Maceiras M; CIBER of Cancer (CIBERONC), 28029 Madrid, Spain.
  • Castel V; Department of Pathology, Medical School, University of Valencia-INCLIVA, 46010 Valencia, Spain.
  • Navarro S; CIBER of Cancer (CIBERONC), 28029 Madrid, Spain.
  • Noguera R; Department of Pathology, Medical School, University of Valencia-INCLIVA, 46010 Valencia, Spain.
Cancers (Basel) ; 13(20)2021 Oct 15.
Article em En | MEDLINE | ID: mdl-34680323
ABSTRACT
Spatial ITH is defined by genomic and biological variations within a tumour acquired by tumour cell evolution under diverse microenvironments, and its role in NB patient prognosis is understudied. In this work, we applied pangenomic techniques to detect chromosomal aberrations in at least two different areas of each tumour and/or in simultaneously obtained solid and liquid biopsies, detecting ITH in the genomic profile of almost 40% of HR-NB. ITH was better detected when comparing one or more tumour pieces and liquid biopsy (50%) than between different tumour pieces (21%). Interestingly, we found that patients with ITH analysed by pangenomic techniques had a significantly better survival rate that those with non-heterogeneous tumours, especially in cases without MYCN amplification. Moreover, all patients in the studied cohort with high ITH (defined as 50% or more genomic aberration differences between areas of a tumour or simultaneously obtained samples) survived after 48 months. These results clearly support analysing at least two solid tumour areas (separately or mixed) and liquid samples to provide more accurate genomic diagnosis, prognosis and therapy options in HR-NB.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article